Approval · Notice of Compliance 20642 · 2018
ATRIPLA: Notice of Compliance 20642
Issued March 20, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20642
- Date
- March 20, 2018
- Company
- Gilead Sciences, Inc.Foster City, California, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATRIPLA | 02300699 | Cancelled Post Market |
Medicinal ingredients
- EFAVIRENZ 600 MG per TAB
- EMTRICITABINE 200 MG per TAB
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB